Experiences of Community-Living Adults With Pressure Injuries: A Qualitative Systematic Review With Thematic Synthesis.

Importance: Occupational therapy practitioners provide interventions to adults with pressure injury (PI) in their home. However, little is known about these adults' experiences of living with PI in the home environment. Current guidelines are biomedically focused and based on research primarily in hospital or institutional settings.

Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL.

Early identification of patients at risk for immune effector cell-associated hematotoxicity (ICAHT) is essential to minimize non-relapse mortality. The CAR-HEMATOTOX (HT) score is an implemented risk-stratification tool for ICAHT, infections and survival in relapsed/refractory large B-cell lymphoma (R/R LBCL) patients receiving CAR T-cell therapy (CART). Although validated in its defining study, the HT score was developed in a small cohort, necessitating independent external validation.

Exercise effects on symptoms of depression and anxiety vary by patient, clinical, and intervention characteristics in cancer survivors: Results from pooled analyses of individual participant data of 26 RCTs.

Purpose: This study aimed to investigate whether socio-demographic, clinical, and intervention-related variables moderate the effects of exercise on depression and anxiety symptoms in cancer survivors.

Methods: Data from 26 RCTs in the POLARIS database were analyzed using a one-step individual participant data (IPD) meta-analytic approach with linear mixed models to assess exercise effects on depression and anxiety symptoms (z-scores). Interaction terms were added to these models to explore moderators.

Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma.

Purpose Of Review: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent subtypes of non-Hodgkin lymphoma (iNHL) characterized by a relapsing-remitting disease course. A promising novel therapeutic class emerges with T-cell engaging therapies, which include CD19 directed chimeric antigen receptor T-cell (CAR-T) therapy and CD3xCD20 directed bispecific antibodies (BsABs). This review provides a comprehensive evaluation of their efficacy and safety along with logistical considerations in relapsed/refractory (r/r) iNHL.